Page 1

July 21 , 2021 poxel Poxel Provides Corporate Update and Reports Cash and Revenue for the Second Quarter and First Half 2021 • As of June 30 , 2021 , cash and cash equivalents were EUR 36.9 million ( USD 43.9 million ) which includes EUR 13.5 million from the third and final tranche of IPF loan triggered by the recent approval of the Company's lead drug candidate TWYMEEGⓇ ( Imeglimin ) in Japan • Poxel to receive JPY 1.75 billion ( approximately EUR 13.2 million , USD 15.8 million ) 1 milestone payment from Sumitomo Dainippon Pharma in Q3 2021 following TWYMEEG approval ; product launch in Japan expected in 2021 • In rare metabolic diseases , PXL065 and PXL770 Phase 2a clinical Proof - of- Concept ( POC ) studies in X - linked adrenoleukodystrophy ( ALD ) expected to initiate in early 2022 with data expected in Q4 2022 • In non - alcoholic steatohepatitis ( NASH ) , patient enrollment in PXL065 DESTINY Phase 2 trial expected to be complete in Q3 2021 with results expected in Q3 2022 LYON , France -- ( BUSINESS WIRE ) -- POXEL SA ( Euronext - POXEL - FR0012432516 ) , a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology , including non - alcoholic steatohepatitis ( NASH ) and rare disorders , today announced its cash position and revenue for the second quarter and first half of 2021 . " Following our recent achievements , we are excited to leverage our proven capabilities and existing platforms to execute upon our new strategic direction - an increased focus on rare metabolic diseases , along with our continued commitment to NASH , " said Thomas Kuhn , CEO of Poxel . “ The recent TWYMEEG approval in Japan is a major milestone for Poxel . It enhances our financial foundation allowing us to pursue our development goals in rare metabolic indications where we can be more efficient with our resources and more expediently deliver novel medicines to patients with an even stronger potential to create significant value for the benefit of our shareholders . This approval is the culmination of years of clinical development work and a strong validation for both our R & D capabilities and the international footprint that we have established . " Clinical Development Updates Rare metabolic diseases :